Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3081 - Evaluation of the conversion rate in Ki-67, estrogen receptor (ER), progesterone receptor (PR) and HER2 between primary breast cancer and relapse and their value as a prognostic factor


10 Oct 2016


Poster display


Isabel Blancas López-Barajas


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


I. Blancas López-Barajas1, A. Muñoz2, M. Legerén3, F. Galvez1, R. González1, J.M. Jurado1, C.J. Rodriguez1, M. Delgado1, B. Gonzalez Astorga1, M. Yélamos1, S. Sequero3, V. Chacon3

Author affiliations

  • 1 Oncology, Hospital Clinico San Cecilio, 18012 - Granada/ES
  • 2 Medicina, Facultad de Medicina. Universidad de Granada, Granada/ES
  • 3 Oncology, Hospital Clinico San Cecilio, Granada/ES


Abstract 3081


The aims are to asses the different expression of ER, PR, HER2 and Ki-67 between primary tumor and the recurrence and theirs prognostic consequences.


Observational retrospective unicentric study of 45 breast cancer patients. We have two different populations: patients who have a local and complete resected relapse (LR) and patients with a metastatic biopsied disease (MD).The changes in ER, PR, HER2 and Ki-67 between the pathologist report of primary tumor and the biopsy of the relapse have been analyzed. We studied ER, PR, HER2 and Ki-67 determined in the relapse as prognostic factor for relapse free survival (RFS) and overall survival (OS) in the LR group, and for progression-free survival (PFS) and OS in MD group.


The conversion rate of 34,8% for Ki-67 (p = 0,046), 20% for ER (p = 0,001), 20% for PR (p 


We observed a significative conversion rate in Ki-67, ER, PR and HER2 between primary breast cancer and relapse. We saw that ER- in the local relapse or metastasis, as well as a PR- in the metastasis were associated with a worse prognosis.

Clinical trial identification

Legal entity responsible for the study

Hospital Clinico San Cecilio Granada


Hospital Clinico San Cecilio Granada


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings